Actionable news
All posts from Actionable news
Actionable news in INFI: Infinity Pharmaceuticals, Inc.,

Infinity: Jaren Irene Madden, Senior Director,

The following excerpt is from the company's SEC filing.

Investor Relations and Corporate Communications

617-453-1336 or

Christi Waarich

Senior Manager, Investor Relations

617-453-1363 or




Topline DYNAMO Data Anticipated in the Third Quarter of 2016, Company Anticipates

Global Regulatory Filings by Year-End 2016

Clinical Study of Duvelisib in Combination with Venetoclax Expected to

Begin by Year-End

Two Additional iNHL Studies of Duvelisib, BRAVURA and FRESCO, Expected to Begin

Phase 1 Study of IPI-549 Expected to Begin in the First Quarter of 2016

Provides Updated 2015 Financial Guidance

Cambridge, Mass. October 6, 2015

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will provide an update on the clinical development program and commercial overview for duvelisib, an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, and discuss the companys immuno-oncology development candidate, IPI-549, at its Research and Development (R&D) Day this morning from 8:00am (ET) to 11:45am (ET) in New York City. During todays presentations, Infinity will review its anticipated timelines for the development and commercialization of duvelisib. The company recently announced that the 120

patient has been enrolled in DYNAMO

, a Phase 2 study in patients with refractory indolent non-Hodgkin lymphoma (iNHL), and topline data from this study are anticipated in the third quarter of 2016. Infinity will also review the IPI-549 data presented at the CRI-CIMT-EATI-AACR International

Cancer Immunotherapy Conference and discuss the planned Phase 1 study for IPI-549 in solid tumors.

We are entering into an exciting time for Infinity, stated Julian Adams, the companys president, research and development. During our R&D Day, we will provide a thorough review of our duvelisib program, including preclinical and clinical data that support our registration focused trials in iNHL and CLL, DYNAMO and DUO, respectively, and outline our clinical development strategy to further differentiate duvelisib. We are extremely pleased to have some of the top experts in leukemia, lymphoma and immuno-oncology to provide the physicians perspective based on their knowledge and experience, and we also look forward to sharing the innovative science that led to IPI-549.

Today Infinity also announced that William (Bill) Bertrand has been appointed to the role of executive vice president, general counsel, effective October 19, 2015, reporting to Adelene Perkins, chair, president and chief executive officer.

Bill has tremendous experience along the entire biotechnology value chain from preclinical through commercialization as the first and only general counsel of MedImmune and most recently, as the chief operating officer and general manager of Salix prior to its acquisition by Valeant this summer, stated Adelene Perkins, Infinitys president and chief executive officer. Bill will serve on Infinitys senior executive leadership team and play an important role in helping us build the company and bring duvelisib to patients.

During todays R&D day, we look forward to sharing our vision for Infinity as well as providing an update on our development programs. With the recent completion of patient enrollment in DYNAMO, our ongoing duvelisib trials, the start of important new trials later this year, and the expansion of our pipeline with IPI-549, we are taking key steps toward our goal of delivering important new medicines to patients that could make a meaningful difference in their lives.

To listen to the live audio webcast and view the slide presentations, please visit the Investors/Media section of Infinitys website, A replay will also be available and archived on the site for approximately 90 days.

R&D Day Highlights

patient enrolled in DYNAMO:

In September, Infinity announced that the 120

patient had been enrolled in DYNAMO, a global, Phase 2 open-label, single-arm, monotherapy study of duvelisib (25 mg BID) in patients with iNHL whose disease is refractory to rituximab and to either chemotherapy or radioimmunotherapy. The primary endpoint is overall response rate. Topline data is anticipated in the third quarter of 2016, and Infinity anticipates the submission of global regulatory filings by the end of 2016. This enrollment milestone triggered an obligation for AbbVie Inc. to pay Infinity a $130 million payment. AbbVie is Infinitys global development and commercial partner for duvelisib in oncology.

enrollment on track for completion by the end of 2015:

Infinity expects that DUO, a Phase 3 randomized monotherapy study designed to evaluate the safety and efficacy of duvelisib (25mg BID) compared to ofatumumab in approximately 300 patients with relapsed/refractory chronic lymphocytic leukemia (CLL), will complete patient enrollment by the end of 2015. The primary endpoint of this study is...